My uncle spent the last years of his life fighting prostate cancer, waiting for medications that kept getting delayed, ...

These people shape everything from treatment availability to insurance plans and real-world results for patients.

Rituximab is poised for growth due to its established use in oncology and autoimmune diseases, strong commercial history, and proven efficacy. Despite biosimilar competition, its broad indications and ...

Nuclear weapons testing gave her cancer. She has spent the past 30 year making sure the U.S. government couldn't look away.

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...

Fixed-duration CLL treatment is changing management options for the condition. Here’s what it is, how it works, its potential ...

Chronic lymphocytic leukemia (CLL) is often a chronic disease; many patients receive more than one treatment over the course ...

The treatment landscape of chronic lymphocytic leukaemia has undergone a revolution in the past decade. Highly effective ...

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short. What does it actually cost—in dollars, in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Kerry Rogers, MD, discusses financial toxicity, equitable access to BTK inhibitors, and how frailty shapes CLL clinical trial design. On cost, Rogers noted that although her institution’s Medication ...

Investigators conducted a retrospective study of patients treated for early-stage breast cancer at Fred Hutch Cancer Center to identify clinicopathologic factors associated with SLN-positivity (SLN+), ...